NL7908936A - Werkwijze voor het bereiden van vaccins. - Google Patents
Werkwijze voor het bereiden van vaccins. Download PDFInfo
- Publication number
- NL7908936A NL7908936A NL7908936A NL7908936A NL7908936A NL 7908936 A NL7908936 A NL 7908936A NL 7908936 A NL7908936 A NL 7908936A NL 7908936 A NL7908936 A NL 7908936A NL 7908936 A NL7908936 A NL 7908936A
- Authority
- NL
- Netherlands
- Prior art keywords
- virus
- immunocomplex
- soluble
- hsv
- antibody
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims description 40
- 238000000034 method Methods 0.000 title claims description 19
- 241000700605 Viruses Species 0.000 claims description 47
- 239000000427 antigen Substances 0.000 claims description 37
- 102000036639 antigens Human genes 0.000 claims description 36
- 108091007433 antigens Proteins 0.000 claims description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 241000894007 species Species 0.000 claims description 10
- 102000003886 Glycoproteins Human genes 0.000 claims description 8
- 108090000288 Glycoproteins Proteins 0.000 claims description 8
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 8
- 241000700584 Simplexvirus Species 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 5
- 108010044091 Globulins Proteins 0.000 claims description 4
- 102000006395 Globulins Human genes 0.000 claims description 4
- 230000003622 anti-hsv Effects 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000568 immunological adjuvant Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 23
- 239000000463 material Substances 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 239000006166 lysate Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 241000700198 Cavia Species 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 108010074605 gamma-Globulins Proteins 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000000464 low-speed centrifugation Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 229940028617 conventional vaccine Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 238000000760 immunoelectrophoresis Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 101100245381 Caenorhabditis elegans pbs-6 gene Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- -1 with the soluble Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/087—Herpes simplex virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1278878 | 1978-12-15 | ||
| CH1278878 | 1978-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL7908936A true NL7908936A (nl) | 1980-06-17 |
Family
ID=4386405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL7908936A NL7908936A (nl) | 1978-12-15 | 1979-12-12 | Werkwijze voor het bereiden van vaccins. |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JPS5589231A (fr) |
| AU (1) | AU5379079A (fr) |
| BE (1) | BE880620A (fr) |
| CA (1) | CA1153309A (fr) |
| DE (1) | DE2949031A1 (fr) |
| FR (1) | FR2443839A1 (fr) |
| GB (1) | GB2037165A (fr) |
| IL (1) | IL58947A (fr) |
| IT (1) | IT7951051A0 (fr) |
| NL (1) | NL7908936A (fr) |
| PH (1) | PH15412A (fr) |
| SE (1) | SE7910089L (fr) |
| ZA (1) | ZA796820B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5219567A (en) * | 1982-03-24 | 1993-06-15 | The University Of Birmingham | Vaccine against herpes viruses |
| IL68219A0 (en) * | 1982-03-24 | 1983-06-15 | Univ Birmingham | Vaccine against dna viruses |
| CA1201987A (fr) * | 1982-03-24 | 1986-03-18 | Gordon R.B. Skinner | Vaccin contre les virus a adn |
| NZ209307A (en) * | 1983-08-30 | 1990-07-26 | Genentech Inc | Diagnostic product: antigenic peptide produced by recombinant dna techniques |
| NZ209308A (en) * | 1983-08-30 | 1991-08-27 | Genentech Inc | Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein |
| ES2216280T3 (es) * | 1997-04-08 | 2004-10-16 | MERCK & CO., INC. | Formulaciones estabilizadas de papilomavirus humano. |
| WO2020033742A1 (fr) * | 2018-08-08 | 2020-02-13 | Trellis Bioscience, Llc | Vaccins passifs et actifs améliorés contre le rsv |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU56161A1 (fr) * | 1968-05-28 | 1970-01-14 | ||
| US3652761A (en) * | 1969-09-04 | 1972-03-28 | Corning Glass Works | Immunochemical composites and antigen or antibody purification therewith |
| FR2222084B1 (fr) * | 1973-03-22 | 1976-05-14 | Fontaine Michel | |
| US3873690A (en) * | 1974-01-23 | 1975-03-25 | Iii James H Rand | Equine infectious anemia vaccine |
-
1979
- 1979-12-06 DE DE19792949031 patent/DE2949031A1/de not_active Withdrawn
- 1979-12-07 SE SE7910089A patent/SE7910089L/xx not_active Application Discontinuation
- 1979-12-11 IT IT7951051A patent/IT7951051A0/it unknown
- 1979-12-11 GB GB7942733A patent/GB2037165A/en not_active Withdrawn
- 1979-12-11 FR FR7930341A patent/FR2443839A1/fr active Granted
- 1979-12-12 NL NL7908936A patent/NL7908936A/nl not_active Application Discontinuation
- 1979-12-13 AU AU53790/79A patent/AU5379079A/en not_active Abandoned
- 1979-12-13 IL IL58947A patent/IL58947A/xx unknown
- 1979-12-13 CA CA000341913A patent/CA1153309A/fr not_active Expired
- 1979-12-14 BE BE1/9646A patent/BE880620A/fr not_active IP Right Cessation
- 1979-12-14 PH PH23417A patent/PH15412A/en unknown
- 1979-12-14 ZA ZA00796820A patent/ZA796820B/xx unknown
- 1979-12-14 JP JP16344879A patent/JPS5589231A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SE7910089L (sv) | 1980-06-16 |
| BE880620A (fr) | 1980-06-16 |
| FR2443839A1 (fr) | 1980-07-11 |
| IL58947A (en) | 1983-10-31 |
| JPS5589231A (en) | 1980-07-05 |
| IL58947A0 (en) | 1980-03-31 |
| CA1153309A (fr) | 1983-09-06 |
| AU5379079A (en) | 1980-06-19 |
| PH15412A (en) | 1983-01-07 |
| FR2443839B1 (fr) | 1983-10-07 |
| DE2949031A1 (de) | 1980-07-17 |
| GB2037165A (en) | 1980-07-09 |
| IT7951051A0 (it) | 1979-12-11 |
| ZA796820B (en) | 1981-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eberle et al. | Preparation and characterization of specific antisera to individual glycoprotein antigens comprising the major glycoprotein region of herpes simplex virus type 1 | |
| Gratama et al. | Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. | |
| Fischinger et al. | Neutralization of homologous and heterologous oncornaviruses by antisera against the p15 (E) and gp71 polypeptides of Friend murine leukemia virus | |
| Dierks et al. | Extraneural rabies virus infection. Virus development in fox salivary gland. | |
| Falconar et al. | Immunoaffinity purification of native dimer forms of the flavivirus non-structural glycoprotein, NS1 | |
| CA1244766A (fr) | Vaccin de sous-unite de virus de l'herpes simplex | |
| EP0048201B1 (fr) | Vaccin à base d'une fraction du virus herpes simplex type I et procédé de préparation | |
| Lightman et al. | Do L3T4+ T cells act as effector cells in protection against influenza virus infection. | |
| Nakamura et al. | Differential susceptibility and resistance of immunocompetent and immunodeficient mice to fatal Hantaan virus infection | |
| CA1174168A (fr) | Vaccin contre la leucemie feline | |
| NL7908936A (nl) | Werkwijze voor het bereiden van vaccins. | |
| Grose et al. | Immunoprecipitable polypeptides specified by varicella-zoster virus | |
| Stannard et al. | An Fc receptor for human immunoglobulin G is located within the tegument of human cytomegalovirus | |
| Hampar et al. | Mechanism of persistent herpes simplex virus infection in vitro | |
| JPH09110719A (ja) | 実質的には非宿主アルブミンを含有しないアジユバント化ワクチン | |
| Frank et al. | Rhesus Leukocyte-associated Herpesvirus. I. Isolation and Characterization of a New Herpesvims Recovered from Rhesus Monkey Leukocytes | |
| Grose et al. | Immunogenic glycoproteins of laboratory and vaccine strains of varicella-zoster virus | |
| Crumpacker | Viral glycoproteins in infectious disease processes | |
| Klein et al. | Precipitating antibodies in experimental visna and natural progressive pneumonia of sheep | |
| Henson et al. | Murine cytomegalovirus: observations on growth in vitro, cytopathic effect, and inhibition with 5-Iododeoxyuridine | |
| Campbell et al. | Present trends and the future in rabies research | |
| US4540669A (en) | Herpes simplex type I subunit vaccine | |
| Tsukiyama et al. | Effect of platelet-derived factor on expression of bovine leukemia virus genome | |
| JPH0211524A (ja) | オーエスキー病ワクチンの製造方法及び該ワクチン接種豚と自然感染豚との識別方法 | |
| Jilg et al. | Diagnostic significance of antibodies to the Epstein-Barr virus-specific membrane antigen gp250 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BV | The patent application has lapsed |